Logo
ALIDYA Anti Lipodystrophic Agents

ALIDYA Anti Lipodystrophic Agents

Alidya

Medical aesthetic product
  • CE Marked injectable medical device for the treatment and prevention of gynoid lipodystrophy (cellulite) in the EU/EEA
  • Manufactured in compliance with applicable European medical device regulations for Class III injectable devices
  • Intended exclusively for use by qualified medical professionals
Injectable mesotherapy / cellulite (gynoid lipodystrophy) treatment

Description

ALIDYA Anti-Lipodystrophic Agents is a CE-marked injectable mesotherapy device specifically formulated to treat and prevent gynoid lipodystrophy (cellulite) and its visible effects such as orange-peel skin. The product consists of 5 vials of lyophilised powder (340 mg each) and 5 vials of solvent (10 ml each) that are mixed immediately before use to form a clear or slightly pink solution. Based on a polyamino acid gel and a synergistic blend of amino-acid–based and chelating ingredients, Alidya improves microcirculation, detoxifies tissue by chelating metal ions and toxins, restructures adipose tissue, and enhances skin firmness and elasticity. It is intended for professional mesotherapy use on cellulite-prone areas such as the thighs, buttocks, abdomen, hips, knees, arms and shoulders.

Bnefits

  • Reduces the visible appearance of cellulite and orange-peel skin
  • Treats and helps prevent gynoid lipodystrophy in cellulite-prone areas
  • Improves microcirculation and tissue oxygenation in the treated area
  • Detoxifies tissue by chelating heavy metals and reducing toxic metabolites
  • Supports collagen production and tissue restructuring for firmer, smoother skin
  • Non-surgical, minimally invasive mesotherapy treatment
  • Can improve contour and skin quality after liposuction or intralipotherapy
  • Provides results that can last up to about 12 months with maintenance treatments

Indications

  • Treatment and prevention of gynoid lipodystrophy (cellulite)
  • Visible cellulite and orange-peel skin on thighs, buttocks, hips and abdomen
  • Cellulite on knees, upper arms, shoulders and other localised areas
  • Irregularities and skin changes following liposuction
  • Irregularities and skin changes after fat-dissolving (intralipotherapy) treatments
  • Patients showing early signs of cellulite who wish to prevent progression

Composition

  • Polyamino acid gel (polyaminoacid gel)
  • D-(+) alpha-D-glucopyranose (D-glucopyranose, 1–4 glycosidic structure)
  • Mannitol
  • Sodium ethylenediaminetetraacetate (EDTA)
  • Amino acid buffer system with sodium bicarbonate corrector
  • Osmolarity regulator
  • Mixture of amino acids (primary active base)
  • Physiological excipients and solvent for reconstitution

Formulation

  • Injectable anti-lipodystrophic mesotherapy solution formed by reconstituting lyophilised powder with solvent immediately before use
  • Sterile, non-pyrogenic, physiological gel solution for intradermal or subcutaneous injection
  • CE-marked medical device intended for professional mesotherapy use only

Packaging

  • Box containing 5 vials of lyophilised powder, 340 mg each
  • 5 vials of solvent, 10 ml each
  • Powder and solvent are mixed in a single vial prior to administration to obtain the injectable solution
  • Pack also labelled for batch/lot traceability and expiry date

Usage

  • For professional use only; treatment must be performed by a qualified healthcare professional trained in mesotherapy techniques.
  • Aseptically transfer the 10 ml solvent from one vial into a vial containing 340 mg lyophilised powder using a sterile syringe.
  • Gently shake the vial for a few seconds until the solution becomes clear or slightly pink; a characteristic odour may be present and is considered normal.
  • Disinfect the treatment area thoroughly before injection.
  • Inject the reconstituted solution using mesotherapy technique into the deep dermis or subcutaneous tissue of the cellulite-affected area (typically with a fine needle such as 30G).
  • Administer multiple 0.2–0.3 ml micro-bolus injections across the treatment area, adjusting total volume according to the size of the area and patient body habitus (commonly 1–2 vials per session).
  • Perform sessions once weekly; a typical initial course is 7–12 treatment sessions depending on cellulite severity.
  • Advise the patient to avoid excessive heat exposure (sun, sauna), vigorous exercise and cosmetics on the treated area for a short period after treatment, and to maintain good hydration.
  • After completion of the initial course, repeat maintenance sessions approximately once per year (or as clinically indicated) to sustain results.

Contraindications

  • Pregnancy and breastfeeding
  • Patients under 18 years of age or over 65 years of age
  • Known hypersensitivity or allergy to any component of the product (e.g. amino acids, mannitol, EDTA or excipients)
  • Active skin infection, inflammation or dermatological disease in the proposed treatment area
  • Autoimmune diseases
  • Significant hepatic (liver) or renal (kidney) impairment
  • Significant lymphatic system disorders
  • Current or recent anticoagulant or blood-thinner therapy (unless carefully assessed by the treating physician)
  • Any serious systemic illness or condition that, in the clinician’s judgement, makes treatment inappropriate

Adverse Effects

  • Transient redness (erythema), swelling and bruising at injection sites
  • Mild itching, tenderness or skin sensitivity in the treated area
  • Tingling or warmth/heat sensation at the injection sites
  • Small nodules or tissue induration (hardening) in the injected area
  • Temporary changes in skin colour at injection sites
  • Mild, transient pain or discomfort during or shortly after injection
  • As with any injectable treatment: rare risk of infection, allergic reaction or more pronounced inflammatory response

Storage Conditions

  • Store in original packaging until use.
  • Keep at controlled room temperature, typically between 2 °C and 25 °C.
  • Protect from extreme heat and cold; do not freeze.
  • Use only within the expiry date printed on the packaging.
  • After reconstitution, use the solution promptly in accordance with the manufacturer’s instructions and do not store partially used vials.

Duration

Standard protocol: 7\u201312 weekly mesotherapy sessions for each treatment course, with 1\u20132 vials per session depending on area size and severity; maintenance treatments are generally recommended once per year to prolong results.

Onset

Early improvements in skin texture and reduction in cellulite appearance are typically seen after the first few sessions, with optimal smoothing and firming usually evident after completion of the full 7\u201312 session course.

Browse more Medical aesthetic product

Top Treatments

Top Cities in the UK